New hope for tough lung cancer: experimental drug takes on chemo

NCT ID NCT06382129

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial compares a new drug called BL-B01D1 to the standard chemo docetaxel in 698 people with advanced non-small cell lung cancer that has not responded to prior immunotherapy and chemo. The goal is to see if BL-B01D1 helps people live longer. Participants receive either drug by IV every 3 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (a drug given by IV)
What this could lead to: If it works, this could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong: This is a large Phase 3 trial, but the drug is still experimental. It may not improve survival or could have side effects like other chemotherapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.